… of dendritic cells in the COVID-19 immunopathogenesis. Despite the expected susceptibility
… Considering the complexity of COVID-19, it is likely that a multiple therapy approach may be …

… (27), A therapeutic clinical trial could shed light on the impact of such immunomodulatory
action on the morbidity and mortality of seriously ill COVID-19 infected patients. …

… cortisol levels for hormone therapy, and dexamethasone can reduce COVID-19 mortality in
critically … In any case, the practicality of employing hormonal therapies in COVID-19 should be …

… immune abnormalities in patients with COVID-19. There is growing … the immunopathogenesis
of COVID-19 which will lay the foundation for the development of new potential therapies. …

… named the novel coronavirus that caused covid-19 outbreak as Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Covid-19 is not the first coronavirus outbreak, rather …

… We thematically focus on the immunopathogenesis of COVID-19 and related CoVs, clinical
… , inflammatory mediators are potential targets for the anti-infectious therapy of COVID-19. …

… studies drugs that suppressed the immune system (anti-inflammatory drugs) may be beneficial
in high risk patient to decrease flood of cytokine in the lung besides anticoagulant therapy …

… COVID-19 and the cytokine storm associated with COVID-19. This paper reviews the
immunopathogenesis and immunogenetic variants that play a role in COVID-19. Although various …

… system in overcoming COVID-19 is indisputable, and many therapeutic and preventive …
to combat COVID-19 is presented with a focus on convalescent plasma therapy, antibodies, …

… -6R) are therapeutic regimens proscribed for treating rheumatoid arthritis. They were later
approved to treat cytokine release syndrome in chimeric antigen receptor T-cell therapies (Ref. …